MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/apt.70265

Медицинская библиотека · Alimentary pharmacology & therapeutics · 2025

MELD 3.0 Improves Risk Stratification and Mortality Prediction in Hepatorenal Syndrome-Acute Kidney Injury: A Multicentre Study.

Ma Jing, Chen Xinyi, Zhou Qin, Chen Jingyi, Yang Guanghong, Pan Qiaoling, Huang Chenjie, Luo Rui, Lu Xiaoqing, Chen Xiaoxiao, Li Tan, Huang Haijun, Li Lanjuan, Cao Hongcui, Yu Jiong

Сравнительное исследованиеСтатьяМногоцентровое исследованиеПеревод в очереди

Аннотация

BACKGROUND

Hepatorenal syndrome-acute kidney injury (HRS-AKI) is a life-threatening complication in decompensated cirrhosis with limited predictive tools for short-term prognosis. Traditional models such as MELD, MELD-Na and Child-Turcotte-Pugh (CTP) have notable limitations in this population.

AIMS: This study aimed to evaluate the prognostic performance of the newly developed MELD 3.0 score in predicting 90-day mortality among patients with HRS-AKI.

METHODS

In this multicentre retrospective cohort study, 539 patients with HRS-AKI were enrolled from three tertiary hospitals between 2015 and 2023. The predictive performance of MELD 3.0 for 90-day mortality was systematically compared with MELD, MELD-Na, and CTP scores through ROC curve (AUC) and net reclassification improvement (NRI) analysis.

RESULTS

MELD 3.0 demonstrated the highest predictive performance for 90-day mortality (AUC = 0.812), significantly surpassing MELD (AUC = 0.790, p = 0.006), MELD-Na (AUC = 0.791, p = 0.002) and CTP (AUC = 0.756, p = 0.005). It was an independent predictor of mortality (HR = 1.13 per point, 95% CI: 1.11-1.16, p < 0.001) and achieved significant NRI over MELD (7.05%), MELD-Na (6.01%) and CTP (13.75%). Its predictive performance remained robust across ACLF severity, age subgroups and treatment response profiles.

CONCLUSION

This is the first large-scale study to validate MELD 3.0 in HRS-AKI. By offering enhanced discrimination and clinically meaningful reclassification, MELD 3.0 provides a more refined tool for early risk stratification, with potential to guide timely intervention, inform transplant decisions and improve personalized care in this critically ill population.

Для цитирования: Ma Jing, Chen Xinyi, Zhou Qin, Chen Jingyi, Yang Guanghong, Pan Qiaoling, Huang Chenjie, Luo Rui, Lu Xiaoqing, Chen Xiaoxiao, Li Tan, Huang Haijun, Li Lanjuan, Cao Hongcui, Yu Jiong. MELD 3.0 Improves Risk Stratification and Mortality Prediction in Hepatorenal Syndrome-Acute Kidney Injury: A Multicentre Study.. Alimentary pharmacology & therapeutics. 2025. DOI: 10.1111/apt.70265.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.